AbstractObjectives. Cost-effectiveness thresholds inform whether health interventions represent good value for money, yet their use varies across countries

Two-thirds of pharmaceutical companies did not proactively release the launch price of their medications from 2022 to 2024.

Examining whether negotiated prices align with value is one way of asking if CMS “got pricing right” and if the Medicare program is getting its money’s worth.

Examining whether negotiated prices align with value is one way of asking if CMS “got pricing right” and if the Medicare program is getting its money’s worth.

Direct-to-patient programs offer a glimpse of an alternative future in which the consumer or the employer is brought closer to the manufacturer of the medicine prescribed.

Direct-to-patient programs offer a glimpse of an alternative future in which the consumer or the employer is brought closer to the manufacturer of the medicine prescribed.

Subscription and open access journals from Sage, the world's leading independent academic publisher.

Objective To examine trends in the inclusion of societal costs in published cost-effectiveness analyses (CEAs), factors associated with their inclusion, and the...

This Viewpoint examines variations in US commercial health plan coverage restrictions for cell and gene therapies.

In this piece, we present remembrances of John from several of the countless people whose lives John touched personally and professionally.

INTRODUCTION Older adults with dementia incur considerable out-of-pocket (OOP) health care expenses, but it is unclear how their financial burden differs by dementia stage. METHODS We identified 2...

To analyze published cost-effectiveness analyses (CEAs) for the 15 drugs selected for the Initial Price Applicability Year 2027 by the Centers for Medicare and Medicaid Services (CMS).

Vanderbilt recently hosted 11 international fellows to provide training to help them address public health issues in their home countries.

Overview The Tufts University Graduate School of Biomedical Sciences (GSBS) Clinical and Translational Science (CTS) Graduate Program is delighted to offer an accredited Certificate Program in Health ...

Cost-effectiveness analyses (CEAs) generate extensive data that can support much health economic research. However, manual data collection is time-consuming and prone to errors. Development in Artific...

This JAMA Forum discusses some key considerations for addressing the question of whether and when prevention interventions are worth the cost.

Potential Medicare coverage reforms, such as eliminating Coverage with Evidence Development, would remove key policy tools available to CMS. Instead, efforts should focus on more efficient post-market...

Potential Medicare coverage reforms, such as eliminating Coverage with Evidence Development, would remove key policy tools available to CMS. Instead, efforts should focus on more efficient post-market...

Potential Medicare coverage reforms, such as eliminating Coverage with Evidence Development, would remove key policy tools available to CMS. Instead, efforts should focus on more efficient post-market...

Featured podcasts by Leerink Partners – Sharing our insights and interviewing industry leaders to get their perspective.